| Name | Title | Contact Details |
|---|
Our groundbreaking plasma-based materials are designed to improve patient outcomes and reduce healthcare costs across a variety of surgical procedures.
BioVeris Corporation (BioVeris) is a global healthcare and biosecurity company developing technologies in diagnostics and vaccinology. It develops, manufactures and markets its M-SERIES family of products, which can serve as a platform for diagnostic
Taiga Biotechnologies is a privately-held developer of novel therapies for complex diseases including cancers, infectious agents such as HIV and influenza, and hematologic conditions.
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
ChemNavigator is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.